REPLIMUNE GROUP INC
NASDAQ: REPL (Replimune Group, Inc.)
Kemas kini terakhir: semalam, 11:08AM8.88
0.26 (3.02%)
| Penutupan Terdahulu | 8.62 |
| Buka | 8.62 |
| Jumlah Dagangan | 1,964,457 |
| Purata Dagangan (3B) | 7,449,769 |
| Modal Pasaran | 733,244,864 |
| Harga / Buku (P/B) | 3.86 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 15 Jun 2026 |
| EPS Cair (TTM) | -3.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.32% |
| Nisbah Semasa (MRQ) | 7.95 |
| Aliran Tunai Operasi (OCF TTM) | -192.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.31 M |
| Pulangan Atas Aset (ROA TTM) | -31.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Replimune Group, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.10 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.51% |
| % Dimiliki oleh Institusi | 107.50% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SARCHI CHRISTOPHER | - | 9.00 | -12,000 | -108,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -12,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -108,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 9.00 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SARCHI CHRISTOPHER | Pegawai | 01 Jun 2026 | Jual automatik (-) | 12,000 | 9.00 | 108,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 May 2026 | CNBC | Replimune to resubmit twice-rejected drug for approval after FDA shakeup |
| 05 May 2026 | CNBC | FDA commissioner defends agency's drug approval decisions after wave of backlash |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |